Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124807 | 0.92 | POLB (0.44) | TRPM8KMT2AMAPTPOLBL3MBTL1 | |
| SCHEMBL166916 | 0.86 | POLB (0.43) | KMT2ASMN1; SMN2MAPTPOLBL3MBTL1 | |
| SCHEMBL127340 | 0.85 | TRPM8 (0.39) | TRPM8KMT2ASMN1; SMN2MAPTTP53 | |
| SCHEMBL307375 | 0.84 | TRPM8 (0.39) | TRPM8SMN1; SMN2MAPTTP53THRB | |
| SCHEMBL14310291 | 0.84 | TRPM8 (0.39) | TRPM8KMT2ASMN1; SMN2MAPTTP53 | |
| SCHEMBL14303612 | 0.83 | TRPM8 (0.39) | TRPM8KMT2ASMN1; SMN2MAPTTP53 | |
| SCHEMBL307103 | 0.83 | TRPM8 (0.38) | TRPM8SMN1; SMN2MAPTTP53THRB | |
| SCHEMBL305734 | 0.82 | TRPM8 (0.38) | TRPM8KMT2ASMN1; SMN2MAPTTP53 | |
| SCHEMBL307294 | 0.81 | TRPM8 (0.37) | TRPM8SMN1; SMN2MAPTTP53THRB | |
| SCHEMBL125770 | 0.81 | CYP2C9 (0.49) | POLBL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170334920-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745312-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2011-12-29 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2175859-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | ChemoCentryx Inc (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| WO-2009009740-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | TRPM8 1384/4885KMT2A 3284/4885SMN1; SMN2 4160/4885 |
| US-20170334920-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | TRPM8 878/4885KMT2A 1875/4885SMN1; SMN2 2479/4885 |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | TRPM8 740/4885KMT2A 2475/4885SMN1; SMN2 1898/4885 |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | TRPM8 1237/4885KMT2A 3392/4885SMN1; SMN2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.